Name | AZD-9833 |
---|
Description | Estrogen receptor antagonist 2 is a potent and orally active estrogen receptor (ER) antagonist, example 17, extracted from patent US20180111931A1. Estrogen receptor antagonist 2 is used for the study of breast cancer[1]. |
---|---|
Related Catalog | |
Target |
IC50: estrogen receptor (ER)[1] |
In Vivo | Estrogen receptor antagonist 2 (oral administration; 0.2-50 mg/kg; 20 days) exhibits anti-tumour efficacy as a dose-dependent manner in human parental MCF7 mice xenograft[1]. Estrogen receptor antagonist 2 (oral administration; 0.8-40 mg/kg; 30 days) decreases tumor growth as a dose-dependent manner. It gives almost complete tumour growth inhibition at the doses >10 mg/kg in mice[1]. Animal Model: Human ESR1 mutant breast cancer patient derived xenograft with CTC174 cells in female NSG mice[1] Dosage: 0.8 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 40 mg/kg Administration: Oral administration; 30 days; once daily Result: Inhibited tumor growth in a dose-dependent manner. |
References |
[1]. Bernard Christophe Barlaam, etal. Chemical compounds. Patent US20180111931. |
Molecular Formula | C24H28F4N6 |
---|---|
Molecular Weight | 476.51 |